Quartalsergebnis: Bayer hebt die Jahresziele an – Konzernchef sieht „Wendepunkt“
Nicht nur beim Schuldenabbau kommt der Pharmakonzern voran. Auch das Pharmageschäft entwickelt sich positiver als von den Analysten erwartet. Nun setzt sich der Konzern ambitioniertere Ziele.
Frankfurt - Despite a strong pharmaceutical sector, Bayer delivered a surprisingly robust third quarter in the first half of 2023, offsetting weaknesses in its agricultural division. Adjusted operating profit (EBITDA) rose 6.9 percent to 1.615 billion euros between July and September, surpassing analyst expectations of a decline to 1.425 billion euros.
Overall revenue grew by nearly four percent year-on-year, reaching over ten billion euros. The company's management raised its annual targets, now projecting a net operating profit of 9.8 to 10.3 billion euros, up from previous estimates of 9.6 to 10.1 billion euros. The group also expressed more optimism about debt reduction and free cash flow.
In a notable statement, CEO Bill Anderson said, "We have reached a turning point in the growth development of pharmaceuticals, and we see it going upwards." However, Bayer still faces a significant interest burden as the company earns from rising interest rates, unlike a consumer goods giant.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
